Q-omics provides the consensus-scored PPCDC profile across patient tissues and cancer cell-line models. PPCDC expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PPCDC is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, PPCDC RNA expression shows 19,122 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and BLCA as cancer lineages where PPCDC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPCDC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPCDC survival associations across molecular data types. PPCDC RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPCDC RNA expression–survival associations across cancer types. High PPCDC expression shows unfavorable associations in UVM, LIHC, KICH, LGG, SKCM and LAML. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PPCDC RNA expression.
This table summarizes PPCDC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PPCDC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPCDC shows higher tumor expression in BLCA, LIHC, STAD, BRCA, KIRC and CHOL. The BLCA box plot shows higher PPCDC RNA expression in tumor versus normal tissue (log2 FC = +0.715, t-test p < 0.001).
This table shows molecular features associated with PPCDC in patient tissues and cancer cell lines. In patient samples, PPCDC shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PPCDC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
